FDA Drug Tracking Unlikely To Improve: Attorneys

Law360, New York (April 16, 2008, 12:00 AM EDT) -- While WellPoint Inc.'s plan to monitor rises in health problems among members who take a particular medication will likely be helpful in catching risky side effects, industry initiatives will not curb the sharp need for more post-market tracking by the U.S. Food and Drug Administration, product liability attorneys say.

Shortages in funding and staffing have kept the FDA from adequately policing the 11,000 medications on the market worldwide, attorneys said. And the regulator's voluntary reporting system, called MedWatch, has done little to help spot the majority...
To view the full article, register now.